Citations

Clear

10 citation(s) found for "Lee, Gung".

SenoQuant: One-stop AI software for senescence marker analysis and prediction
Lagnado, Anthony B. , Li, Yukang , Nwakama, Chibuzo C., Franco, Ana Catarina , Han, Yeaeun , Martini, Hélène , Victorelli, Stella, Hruby, Adam , Gomez, Lilian Salez, 우승화, Wyles, Saranya, Khalfaoui, Latifa, Costa, Daniela G. , Khosla, Sundeep, Prakash, YS, Camp, Jon, Holmes, David, Nwakama, Chibuzo, Jurk, Diana , Victorelli, Stella , Lee, Gung , Saul, Dominik , Gomez, Lilian Sales , Wyles, Saranya P. , Khalfaoui, Latifa, Sokka, Miiko , Khosla, Sundeep , Neretti, Nicola , Prakash, YS, Camp, Jon J. , Passos, João F.

Mayo Clinic

No container title available | June 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.18.733222 Get It

Abstract Senescent cells accumulate with age and contribute to tissue dysfunction, yet their identification in tissues is challenging due to low abundance, heterogeneous phenotypes, and the lack of specific markers. Senescence-associated features span multiple subcellular compartments, including nuclear DNA damage foci, cytosolic protein changes, and perinuclear alterations, each requiring tailored detection strategies. To overcome these challenges, we developed SenoQuant ( https://github.com/HaamsRee/senoquant ), a versatile software designed for comprehensive, accurate, and unbiased spatial quantification and prediction of senescence markers across diverse tissue contexts. Utilizing AI models, SenoQuant enables precise nuclear and cytoplasmic segmentation and detection of senescence markers across low- and high-plex imaging modalities, applicable to cultured cells and tissue sections from mice and humans. The platform also supports custom AI models; for example, we built SenCeption, a proof-of-concept predictor of single-cell p21 status from DAPI-stained nuclei in human skin. Available as a free napari plugin, SenoQuant is widely accessible to researchers. By providing a unified approach to senescence analysis and prediction, SenoQuant opens new opportunities for exploring the complex biology of senescence and its impacts on aging and disease.
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
Lanino, Luca , Hunter, Anthony M. , Gagelmann, Nico, Robin, M., Dall'Olio, Daniele , Flamigni, Alice, Gurnari, Carmelo, Wang, Yu‐Hung , Pleyer, Lisa , Xicoy, B., Montalban-Bravo, Guillermo, Shih, Lee-Yung, Alsugair, Ali, Gregorio, Caterina, Platzbecker, Anne Sophie, Sallman, David A., Fariselli, Piero, Garcia-Manero, Guillermo, Platzbecker, U, Solé, Francesc Gessé, Díez-Campelo, María, Maciejewski, Jaroslaw, Bejar, Rafael, Thol, Felicitas, Kroger, N., Fenaux, Pierre, Sanz, G. F., Kordasti, S., Santini, Valeria, Zeidan, Amer M., Komrokji, Rami S., Haferlach, Torsten, Germing, Ulrich, Castellani, Gastone, D'Amico, Saverio, Patnaik, M., Ieva, F., Tefferi, Ayalew, Padron, Eric , Porta, Matteo Giovanni Della, Alliance, for the iCPSS, Haque, Tamanna, Abdel-Wahab, Omar, Geissler, Klaus, Bataller, Alex, Bazinet, Alexandre , Meggendorfer, Manja , Quintavalla, Mirco, Bruseghini, Alessandro , Carota, Luciana , Dall'Olio, Lorenzo, Travaglino, Erica , Zamora, Lurdes López, Quintela, David, Jerez, Andrés , Cornejo, Elena, Martín, Paloma García, Díaz-Beyá, Marina, Pita, Alejandro Avendano, Roldán, Verónica , Suarez, Dolly Viviana Fiallo, Velasco, Estefania Cerezo, Calabuig, Marisa , Such, Esperanza, Castilla-Llorente, Cristina, Bulabois, Claude Eric, Souchet, Laëtitia, Bernardi, Massimo, Chiusolo, Patrizia, Borin, Lorenza, Follo, Matilde Yung, Consagra, Angela , Passamonti, Francesco, Diral, Elisa , Vucinic, Vladan, Bergonzi, Gregorio Maria , Hou, Hsin-An, Russo, Antonio, Tentori, Cristina Astrid , Buizza, Alessandro , Ferrari, Ivan, Matteo, Maria Di, Crespi, Alessandra, Figini, Giulia , Delponte, Camilla, Zampini, Matteo, Riva, Elena, Delleani, Mattia , Iascone, Eleonora, Ficara, Francesca , Ventura, Denise, Pinocchio, Nicole, Santoro, Armando, Kiwan, Ahmad , Ali, Najla H. Al, Zeidan, Amer M. , Robin, Marie , Dall’Olio, Daniele , Riva, Elena , Gagelmann, Nico , Robin, Marie , Sala, Claudia , Gurnari, Carmelo , Wang, Yu-Hung , Shih, Lee‐Yung , Alsugair, Ali , Fathima, Saubia , Gregorio, Caterina , Rollo, Cesare , Platzbecker, Anne Sophie , Asti, Gianluca , Itzykson, Raphael , Sallman, David A , Fariselli, Piero , Kern, Wolfgang , Garcia-Manero, Guillermo , Platzbecker, Uwe , Solé, Francesc , Diez-Campelo, Maria , Maciejewski, Jaroslaw P , Bejar, Rafael , Thol, Felicitas , Savona, Michael R , Sanz, Guillermo F , Kordasti, Shahram , Santini, Valeria , Zeidan, Amer M , Komrokji, Rami S , Castellani, Gastone , D'Amico, Saverio , Patnaik, Mrinal , Ieva, Francesca , Solary, Eric , Padron, Eric , Della Porta, Matteo Giovanni , Buizza, Alessandro , Ficara, Francesca , Lanino, Luca , Gagelmann, Nico , Gurnari, Carmelo , Xicoy, Blanca , Montalban‐Bravo, Guillermo , Fathima, Saubia , Gregorio, Caterina , Palomo, Laura , Itzykson, Raphaël , Sallman, David A. , Kern, Wolfgang , Garcia‐Manero, Guillermo , Platzbecker, Uwe , Solé, Françesc , Díez‐Campelo, María , Thol, Felicitas , Kröger, Nicolaus , Savona, Michael R. , Fenaux, Pierre , Sanz, Guillermo , Santini, Valeria , Fontenay, Michaëla , Komrokji, Rami S. , Haferlach, Torsten , Germing, Ulrich , Solary, Éric , Tefferi, Ayalew , Haque, Tamanna , Bataller, Alex , Sauta, Elisabetta , Sanavia, Tiziana , Dall'Olio, Lorenzo, Díaz‐Beyá, Marina , Roldan, Veronica, Fiallo, Dolly Viviana , Such, Esperanza , Castilla‐Llorente, Cristina , Bulabois, Claude‐Eric , Awada, Hussein , Chiusolo, Patrizia , Curti, Antonio , Giaccone, Luisa , Finelli, Carlo , Casetti, Ilaria Carola , Onida, Francesco , Passamonti, Francesco , Vučinić, Vladan , Voso, Maria Teresa , Hou, Hsin-An, Chou, Wen‐Chien , Yao, Chi‐Yuan , Lin, Chien‐Chin , Tien, Hwei‐Fang , Campagna, Alessia , Ubezio, Marta , Todisco, Gabriele , Maggioni, Giulia , Matteo, Maria Di, Pesce, Francesco , Zampini, Matteo , Crisafulli, Laura , Ventura, Denise , Pinocchio, Nicole , Brindisi, Matteo , VanOudenhove, Jennifer , Ali, Najla H. Al, Graubert, Timothy Aaron , Thota, Swapna , Griffiths, Elizabeth A.

Mayo Clinic

Journal of Clinical Oncology | March 27, 2026 | Volume: 44 | Issue: 17 | Pages: 1608-1623

10.1200/jco-25-02116 | PMID 41894646 Get It

PURPOSE Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm characterized by clinical heterogeneity and is associated with poor outcomes. To date, limited molecular information has been incorporated into disease classification and risk stratification. We aimed to integrate genomic features into the clinical decision-making process for CMML. PATIENTS AND METHODS We analyzed a retrospective cohort of 3013 patients with CMML (training set) and a prospective population of 516 patients (validation set). Using an innovative framework for multimodal data analysis, we developed molecular-based disease taxonomy and prognostication. RESULTS Unsupervised clustering identified nine entities with distinct genomic features and outcomes ( P < .001), including splicing machinery, transcription factors, signal transduction and tyrosine kinase pathways aberrations, and high-risk molecular signatures. Notably, 15% of patients showed molecular/clinical overlap with other myeloid neoplasms. We integrated molecular and clinical information to build the international CMML Prognostic Scoring System (iCPSS), incorporating mutations in nine genes together with hematologic parameters and cytogenetic abnormalities. The iCPSS identified five groups with distinct probability of overall and leukemia-free survival in both training and validation cohorts ( P < .001), outperforming existing prognostic models. Importantly, 55% of patients were reassigned to higher or lower risk groups by the iCPSS. Decision analysis demonstrated that iCPSS could refine the optimal timing of allogeneic transplantation at the individual level; compared with conventional prognostic tools, iCPSS-based decision modeling changed transplantation strategy in 31% of cases, resulting in a significant gain-in-life expectancy for eligible patient population ( P < .001). A federated learning platform was implemented to enable continuous, privacy-preserving model update across multiple centers. CONCLUSION Molecular information improves CMML classification and prognostication, supports more effective clinical decision making, and potentially refines the design of clinical trials.
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
Dall'Olio, Lorenzo, Pleyer, Lisa , Montalban‐Bravo, Guillermo , Bazinet, Alexandre , Meggendorfer, Manja , Sauta, Elisabetta, Travaglino, Erica , Quintela, David, Jerez, Andrés , Cornejo, Elena, Martín, Paloma García, Roldán, Verónica , Suarez, Dolly Viviana Fiallo, Velasco, Estefania Cerezo, Calabuig, Marisa , Souchet, Laëtitia, Borin, Lorenza, Diral, Elisa , Vučinić, Vladan , Russo, Antonio , Tentori, Cristina Astrid , Buizza, Alessandro, Delleani, Mattia , Consagra, Angela , Kiwan, Ahmad , Ali, Najla H. Al, Sallman, David A. , Garcia-Manero, Guillermo, Follo, Matilde Y. , Maciejewski, Jaroslaw P. , Bejar, Rafael, Thol, Felicitas , Fenaux, Pierre , Haferlach, Torsten, Germing, Ulrich, Patnaik, Mrinal M. , Padron, Eric , Lanino, Luca , Hunter, Anthony M. , Gagelmann, Nico , Robin, Marie , Sala, Claudia , Dall’Olio, Daniele , Gurnari, Carmelo , Dall'Olio, Lorenzo, Wang, Yu‐Hung , Xicoy, Blanca , Shih, Lee‐Yung , Haque, Tamanna Zohra , Abdel‐Wahab, Omar , Geissler, Klaus H. , Bataller, Alex , Casetti, Ilaria Carola , Sauta, Elisabetta , Palomo, Laura , Zamora, Lurdes , Díaz‐Beyá, Marina , Pita, Alejandro Avendaño, Roldan, Veronica, Such, Esperanza , Sanz, Guillermo , Platzbecker, Anne Sophie , Castilla‐Llorente, Cristina , Bulabois, Claude‐Eric , Awada, Hussein , Bernardi, Massimo , Chiusolo, Patrizia , Curti, Antonio , Giaccone, Luisa , Onida, Francesco , Passamonti, Francesco , Bergonzi, Gregorio Maria , Voso, Maria Teresa , Hou, Hsin‐An , Chou, Wen‐Chien , Yao, Chi‐Yuan , Lin, Chien‐Chin , Tien, Hwei‐Fang , Campagna, Alessia , Ubezio, Marta , Todisco, Gabriele , Maggioni, Giulia , Asti, Gianluca , Zampini, Matteo , Riva, Elena , Ficara, Francesca , Santoro, Armando , Carota, Luciana , Sanavia, Tiziana , Rollo, Cesare , VanOudenhove, Jennifer , Fariselli, Piero , Kern, Wolfgang , Garcia‐Manero, Guillermo , Thota, Swapna , Griffiths, Elizabeth A. , Finelli, Carlo , Platzbecker, Uwe , Solé, Françesc , Díez‐Campelo, María , Bejar, Rafael , Kröger, Nicolaus , Itzykson, Raphaël , Graubert, Timothy Aaron , Fontenay, Michaëla , Zeidan, Amer M. , Komrokji, Rami S. , Santini, Valeria , Haferlach, Torsten , Germing, Ulrich , D'Amico, Saverio , Castellani, Gastone , Solary, Éric , Porta, Matteo Giovanni Della

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1003-1003

10.1182/blood-2024-200104 Get It

Background. Study of myeloid neoplasms (MN) has been rapidly transformed by genome characterization. Gene mutations have been reported to influence disease phenotype and risk of disease progression, and the evaluation of mutational status can provide valuable insights to improve the decision-making process. In this international study, we evaluated the clinical impact of mutational screening in patients with CMML, which is characterized by significant clinical and genomic heterogeneity, including a substantial proportion of patients with poor outcomes and unmet needs. Currently, only limited molecular information has been incorporated into CMML classification and prognostication. Methods. We retrospectively collected 3182 CMML patients. We used MOSAIC, an AI-based framework for multimodal analysis in rare cancers (PMID: 38875514) to develop innovative, molecular-based tools for classification and prognostication. An independent validation of the results on 516 prospectively collected patients was performed. Results. Bayesian Networs and Hierarchical Dirichlet Processes were used to identify genomic associations and define a CMML molecular classification. We identified 11 clusters with distinct clinical and genomic features, including splicing machinery, signal transduction and tyrosine kinase pathways aberrations, and high-risk molecular signatures (i.e., AML-like and TP53 mutations). Up to 15% of patients showed clear genomic overlap with other MN. Importantly, extensive multi-color flow cytometry on T lymphocytes, NK and myeloid cells (BD FACSymphony A5 Cell Analyzer) revealed specific immunologic and inflammation signatures associated with molecular subgroups. We then integrated molecular and clinical information to build an international CMML Prognostic Scoring System (iCPSS). We assessed the performance of different statistical and AI-based methods; L1-penalized Cox Model resulted as the best performing method. Selected features included hematological parameters (WBC, Hb, PLT and marrow blasts), cytogenetic abnormalities, and mutations in 10 genes (ASXL1, DNMT3A, EZH2, NRAS, RUNX1, SETBP1, STAG2, TET2, TP53, U2AF1). By Bayesian thresholds optimization, we identified 5 risk classes (i.e., very-low, low, intermediate, high and very-high) with median overall survival (OS) ranging from 99 to 9 months (P&lt;.001), and median leukemia-free survival (LFS) ranging from 210 to 18 months (P&lt;.001). iCPSS provided better patient discrimination across all clinical endpoints compared to currently available prognostic tools, with a Concordance Index (CI) for OS of 0.75 versus 0.62-0.64, respectively. Notably, compared to available scoring systems, up to 40% of patients were reassigned to higher or lower risk classes by the iCPSS. External validation on an independent prospective cohort confirmed that the performance of iCPSS is superior to existing prognostic models (CI for OS 0.71 vs 0.54-0.61, respectively) To demonstrate the clinical utility of iCPSS, we focused on 753 patients who underwent allogeneic stem cell transplantation (HSCT). In multivariable analysis, iCPSS stratified the probability of OS post-HSCT (P&lt;.001) and identified groups of patients with different probabilities of disease relapse, ranging from 9% to 62% (P&lt;.001). We employed a clinical- and genomic-based decision support system (PMID: 38723212) to determine the optimal timing of HSCT. Preliminary analyses indicated that higher-risk patients according to iCPSS (i.e., intermediate, high, and very high) benefit from an immediate HSCT strategy. Lower-risk patients (i.e., very low and low) had life expectancy maximized with delayed HSCT. Modeling decision analysis using iCPSS compared to conventional scores, resulted in a change in transplantation policy for a significant proportion of patients (up to 25%). Conclusion. Molecular information significantly improves the classification of CMML patients, providing a basis for refining diagnostic boundaries with other MN and for a more rational inclusion of patients in clinical trials. The iCPSS demonstrated superior performance over currently available scoring systems and improved HSCT decision making process.
Mitochondrial metabolism and epigenetic crosstalk drive the SASP
Martini, Hélène , Birch, Jodie , Victorelli, Stella , Lagnado, Anthony B. , Pirius, Nicholas, Han, Yeaeun , Havas, Aaron , Jurk, Diana , Adams, Peter D. , Passos, João F. , Victorelli, Stella , Lagnado, Anthony , Franco, Ana, Lee, Gung, Han, Yeaeun , Rowsey, Jennifer, Gaspar-Maia, Alexandre , Havas, Aaron , Porritt, Rebecca , Maddocks, Oliver , Jurk, Diana , Khosla, Sundeep , Adams, Peter , Passos, João F , Marques, Francisco Madeira , Franco, Ana Catarina , Lee, Gung , Rowsey, Jennifer L. , Ismail, Wazim Mohammed , Mazzone, Amelia , Espe, Tianna, Hitosugi, Taro , Li, Ya , Washington, Alexander M. , Murad, Rabi , Lei, Xue , Espíndola‐Netto, Jair Machado , Saul, Dominik , Khosla, Sundeep , Kostallari, Enis , Gaspar‐Maia, Alexandre

Mayo Clinic

No container title available | December 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5278203/v1 | PMID 39678326 Get It

Abstract Senescent cells drive tissue dysfunction through the senescence-associated secretory phenotype (SASP). We uncovered a central role for mitochondria in the epigenetic regulation of the SASP, where mitochondrial-derived metabolites, specifically citrate and acetyl-CoA, fuel histone acetylation at SASP gene loci, promoting their expression. We identified the mitochondrial citrate carrier (SLC25A1) and ATP-citrate lyase (ACLY) as critical for this process. Inhibiting these pathways selectively suppresses SASP without affecting cell cycle arrest, highlighting their potential as therapeutic targets for age-related inflammation. Notably, SLC25A1 inhibition reduces systemic inflammation and extends healthspan in aged mice, establishing mitochondrial metabolism as pivotal to the epigenetic control of aging.
Mitochondrial RNA cytosolic leakage drives the SASP
Victorelli, Stella , Eppard, Madeline, Woo, Seung‐Hwa , Everts, Stacia , Martini, Hélène , Pirius, Nicholas, Franco, Ana Catarina , Han, Yeaeun , Saul, Dominik , Splinter, Patrick L., O’Hara, Steven P. , Valenzuela-Pérez, Lucía , Lee, Hyun Se Kim , Jurk, Diana , Everts, Stacia P A, LaRusso, Nicholas F , Hirsova, Petra , Passos, João F , Jurk, Diana , Kim Lee, Hyun Se , Saul, Dominik , Lee, Gung , Han, Nuan , Liang, Eugene Y., Nóvoa, Eva , Nogueiras, Rubén , Morgenthaler, Olivia , LaRusso, Nicholas F. , Passos, João F.

Mayo Clinic

No container title available | August 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4876596/v1 | PMID 39257994 Get It

Abstract Senescent cells secrete proinflammatory factors known as the senescence-associated secretory phenotype (SASP), contributing to tissue dysfunction and aging. Mitochondrial dysfunction is a key feature of senescence, influencing SASP via mitochondrial DNA (mtDNA) release and cGAS/STING pathway activation. Here, we demonstrate that mitochondrial RNA (mtRNA) also accumulates in the cytosol of senescent cells, activating RNA sensors RIG-I and MDA5, leading to MAVS aggregation and SASP induction. Inhibition of these RNA sensors significantly reduces SASP factors. Furthermore, BAX and BAK plays a key role in mtRNA leakage during senescence, and their deletion diminishes SASP expression in vitro and in a mouse model of Metabolic Dysfunction Associated Steatohepatitis (MASH). These findings highlight mtRNA's role in SASP regulation and its potential as a therapeutic target for mitigating age-related inflammation.
Usability and feasibility of PreventS-MD web app for stroke prevention
Feigin, Valery L. , Krishnamurthi, Rita , Medvedev, Oleg N. , Merkin, Alexander, Nair, Balakrishnan, Jalili-Moghaddam, Shabnam, Barker‐Collo, Suzanne , Ratnasabapathy, Yogini , Skinner, Luke C , Sachdev, Perminder S. , Brainin, Michael , Hankey, Graeme J. , Azarpazhooh, Reza, Bhatia, Anjali , Budinčević, Hrvoje , Child, Nicholas, Chwojnicki, Kamil , Correia, Manuel, Davis, Alan , Devlin, Gerry , Demarin, Vida , Dhamija, Rajinder K. , Ding, Ding , Докова, Клара , Dudley, Makarena , Dyer, Jesse, Edmonds, Misty , Ely, Marcela , Feigin, Svetlana , Fornolles, C, Gall, Seana , Gil, Artyom , George, Ann, Haršány, Michal , Harwood, Matire, Hou, Zeng‐Guang , Ibrahim, Norlinah Mohamed, Ka‘ai, Tania , Kalra, Nidhi , Katzenellenbogen, Judith , Kang, Law Zhe, Kar, Arindam , Kazin, Vitalij, Kamenova, Saltanat , Kondybaeva, A., Lavados, Pablo M, Lee, Tsong‐Hai , Liu, Liping , Mahawish, Karim , Maluchnik, Michał , Martins, Sheila , Mavaddat, Nahal , Mehndiratta, Man Mohan, Oliver, Angela , Öztürk, Şerefnur , Patel, Nikhil, Prakash, B, Roos, Kev, Sekaran, Lakshmanan , Shamalov, N. А. , Solomon, Alina, Suwanwela, Nijasri C., Volevach, Ekaterina , Volný, Ondřej , Wan, Joyce, Withanapathirana, Katila, Welte, Tamara, Wiebers, David O. , Zaidi, Wan Asyraf Wan , Kravchenko, Michael , Barker-Collo, Suzanne , Owolabi, Mayowa , Sachdev, Perminder S , Brainin, Michael , Thrift, Amanda , Hankey, Graeme J , Katzenellenbogen, Judith M , Nair, Balakrishnan, Kravchenko, Michael , Jalili‐Moghaddam, Shabnam , Norrving, Bo , Arroll, Bruce , Thrift, Amanda G. , Abd-Allah, Foad , Akinyemi, Rufus , Bath, Philip M. , Brayne, Carol , Child, Nicholas, Farhoudi, Mehdi , Aziz, Aznida Firzah Abdul , Gabriel, Denis , Gnedovskaya, Elena V. , Harwood, Matire L. N. , Hillis, Argye Elizabeth , Hwang, Kevin O. , Ibrahim, Norlinah Mohamed , Kalra, Nidhi, Karaszewski, Bartosz , Kivipelto, Miia , Lavados, Pablo M. , Mateen, Farrah J. , Mikulík, Robert , Oliver, Angela, Patel, Nikhil, Пирадов, М. А. , Purvis, Tara L. , Reips, Ulf‐Dietrich , Rosand, Jonathan M. , Sahathevan, Ramesh , Silva, Deidre Anne De , Singh, Vinod, Srivastava, M.V. Padma , Taylor, Denise M. , Truelsen, Thomas Clement , Venketasubramanian, Narayanaswamy , Winkler, Andrea Sylvia , Wijeratne, Tissa , Wu, Teddy Y

Mayo Clinic

International Journal of Stroke | July 24, 2023 | Volume: 19 | Issue: 1 | Pages: 94-104

10.1177/17474930231190745 | PMID 37485871 Get It

Background: Most strokes and cardiovascular diseases (CVDs) are potentially preventable if their risk factors are identified and well controlled. Digital platforms, such as the PreventS-MD web app (PreventS-MD) may aid health care professionals (HCPs) in assessing and managing risk factors and promoting lifestyle changes for their patients. Methods: This is a mixed-methods cross-sectional two-phase survey using a largely positivist (quantitative and qualitative) framework. During Phase 1, a prototype of PreventS-MD was tested internationally by 59 of 69 consenting HCPs of different backgrounds, age, sex, working experience, and specialties using hypothetical data. Collected comments/suggestions from the study HCPs in Phase 1 were reviewed and implemented. In Phase 2, a near-final version of PreventS-MD was developed and tested by 58 of 72 consenting HCPs using both hypothetical and real patient (n = 10) data. Qualitative semi-structured interviews with real patients (n = 10) were conducted, and 1 month adherence to the preventive recommendations was assessed by self-reporting. The four System Usability Scale (SUS) groups of scores (0–50 unacceptable; 51–68 poor; 68–80.3 good; >80.3 excellent) were used to determine usability of PreventS-MD. Findings: Ninety-nine HCPs from 27 countries (45% from low- to middle-income countries) participated in the study, and out of them, 10 HCPs were involved in the development of PreventS before the study, and therefore were not involved in the survey. Of the remaining 89 HCPs, 69 consented to the first phase of the survey, and 59 of them completed the first phase of the survey (response rate 86%), and 58 completed the second phase of the survey (response rate 84%). The SUS scores supported good usability of the prototype (mean score = 80.2; 95% CI [77.0–84.0]) and excellent usability of the final version of PreventS-MD (mean score = 81.7; 95% CI [79.1–84.3]) in the field. Scores were not affected by the age, sex, working experience, or specialty of the HCPs. One-month follow-up of the patients confirmed the high level of satisfaction/acceptability of PreventS-MD and (100%) adherence to the recommendations. Interpretation: The PreventS-MD web app has a high level of usability, feasibility, and satisfaction by HCPs and individuals at risk of stroke/CVD. Individuals at risk of stroke/CVD demonstrated a high level of confidence and motivation in following and adhering to preventive recommendations generated by PreventS-MD.
Factors Affecting C5 Viability and Demographic Variability in Two Brachial Plexus Centers
Zelenski, Nicole A. , Joslyn, Nichole A., Lee, Ying-Hsuan, Chuang, David Chwei‐Chin , Lu, Johnny Chuieng‐Yi , Chang, Tommy Nai‐Jen , Spinner, Robert J. , Lee, Ying Hsuan, Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | June 20, 2023 | Volume: 11 | Issue: 6 | Pages: e5073

10.1097/gox.0000000000005073 | PMID 37456133 Get It

Background: Complete brachial plexus injuries are devastating injuries. A viable C5 spinal nerve can offer additional sources of axons and alter surgical treatment. We aimed to determine factors that portend C5 nerve root avulsion. Methods: A retrospective study of 200 consecutive patients with complete brachial plexus injuries at two international centers (Mayo Clinic in the United States and Chang Gung Memorial Hospital in Taiwan) was performed. Demographic information, concomitant injuries, mechanism, and details of the injury were determined, and kinetic energy (KE) and Injury Severity Score were calculated. C5 nerve root was evaluated by preoperative imaging, intraoperative exploration, and/or intraoperative neuromonitoring. A spinal nerve was considered viable if it was grafted during surgery. Results: Complete five-nerve root avulsions of the brachial plexus were present in 62% of US and 43% of Taiwanese patients, which was significantly different. Increasing age, the time from injury to surgery, weight, body mass index of patient, motor vehicle accident, KE, Injury Severity Score, and presence of vascular injury significantly increased the risk of C5 avulsion. Motorcycle (≤150cc) or bicycle accident decreased the risk of avulsion. Significant differences were found between demographic variables between the two institutions: age of injury, body mass index, time to surgery, vehicle type, speed of injury, KE, Injury Severity Score, and presence of vascular injury. Conclusions: The rate of complete avulsion injury was high in both centers. Although there are a number of demographic differences between the United States and Taiwan, overall the KE of the accident increased the risk of C5 avulsion.
Diagnosis and Treatment of Femoral Head Osteonecrosis: A Protocol for Development of Evidence-Based Clinical Practice Guidelines
Cui, Quanjun , Baek, Seung‐Hoon , Drescher, Wolf , Hernigou, Philippe , Jones, Lynne C. , Koo, Kyung‐Hoi , Lee, Mel, Mont, Michael A. , Reichert, Ines , Salem, Hytham S. , Stronach, Ben M., Sugano, Nobuhiko , Zhao, Dewei , Cheng, Edward Y. , Goodman, Stuart B. , Ando, Wataru , Bakker, Caitlin , Kim, Harry K.W. , Kim, Shin‐Yoon , Kim, Tae-Young , Ha, Yong‐Chan , Sakai, Takashi , Sierra, Rafael J. , Yamamoto, Takuaki , Yoon, Byung‐Ho

Mayo Clinic

Surgical Technology Online | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52198/21.sti.38.os1437 | PMID 34043232 Get It

Introduction: There are many treatment options for patients who have osteonecrosis of the femoral head (ONFH) and management strategies vary widely both among and within individual countries. Although many researchers have attempted to elucidate the optimal strategies for managing this disease, the lack of large-scale randomized control trials and the lack of agreement on disease staging have curtailed the development of clear-cut guidelines. Materials and Methods: The Association Research Circulation Osseous (ARCO) group sought to address three questions for the management of patients who have ONFH: 1) What imaging studies are most sensitive and specific for the diagnostic evaluation of patients who have ONFH?; 2) What is the best treatment strategy for preventing disease progression in patients who have pre-collapse lesions?; and 3) What is the best treatment strategy for patients who have post-collapse disease? The Patient, Intervention, Comparison, and Outcome (PICO) format was used to formulate the search strategy for each research question. A systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. ARCO participants have been allocated to three groups, each representing one of the PICO questions. After qualitative and quantitative analysis of the data extracted from studies pertaining to each of the three research questions, a set of evidence-based clinical practice guidelines will be proposed for the management of patients who have ONFH. Discussion: It is not always clear which treatment method is optimal for the management of ONFH. Thus, many surgeons have developed and performed various procedures based on patient-specific factors. As there is no consensus on the optimal treatment for various stages of disease, it was clear that developing evidence-based clinical practice guidelines would provide more structure and uniformity to management of these patients. Therefore, the results of this systematic review will lead to the development guidelines that may improve patient-care strategies and result in better outcomes for patients who have ONFH.
Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Thoennissen, Nils H., Krug, Utz , Lee, Dhong Hyun, Kawamata, Norohiko, Iwanski, Gabriela B., Nagler, Arnon , Raynaud, Sophie , Haferlach, Torsten , Gilliland, D. Gary , Tefferi, Ayalew , Ogawa, Seishi, Koeffler, H. Phillip , Lee, Dhong Hyun, Lasho, Terra L. , Weiss, Tamara, Nowak, Daniel , Kato, Motohiro , Shih, Lee‐Yung , Koren‐Michowitz, Maya , Müller‐Tidow, Carsten , Mesa, Ruben A.

Mayo Clinic

Blood | October 12, 2019 | Volume: 114 | Issue: 22 | Pages: 1280-1280

10.1182/blood.v114.22.1280.1280 Get It

Abstract Abstract 1280 Poster Board I-302 Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF) are defined as clonal hematopoietic stem cell disorders. These disorders show an inherent tendency for transformation into leukemia (MPN-blast phase) which is hypothesized to be accompanied by acquisition of additional genomic lesions. We, therefore, obtained a comprehensive profile of genomic alterations associated with leukemic transformation by using single-nucleotide polymorphism (SNP) array in 88 MPN patients, as well as 71 cases with MPN-blast phase, and correlated these findings with their clinical parameters. A relatively high number of genomic alterations was found in MPN after leukemic transformation with 4.6 ± 0.6 abnormalities per sample compared to only 1.4 ± 0.2 changes per patient in chronic phase (p<0.001). Compared to the cytogenetic data, SNP-chip analysis detected about 47% additional chromosomal changes in the MPN samples, and 31% more in the MPN-blast phase cases, whereas SNP-array allelokaryotyping practically captured all cytogenetic abnormalities in our study population. Several additionally altered regions were detected in patients with MPN-blast phase compared to chronic phase, including both deletion and copy-number neutral-loss of heterozygosity (CNN-LOH) on chromosome 12p (9%) and 21q (9%), involving ETV6 and RUNX1. Notably, deletion and CNN-LOH on 17p involving TP53 were diagnosed in 18% of MPN-blast phase samples, which was highly associated with preceding treatment with alkylating agents (p=0.016). Moreover, trisomy 8, as well as amplification of 8q24.21 involving the MYC gene, were detected in 13% of patients with MPN-blast phase who were almost exclusively negative for the JAK2V617F mutation. Genome-wide inspection of further critical regions with promising new candidate genes involved in the evolution to the MPN-leukemic phase included deletion and CNN-LOH on 7q22.1 (SH2B2) in 18%, duplication/amplification on 19p13.2 (PIN1, ICAM1, CDC37) in 13% and 21q22.2 (ERG) in 9% of MPN patients with blast crisis. In contrast, we detected a decreased frequency of JAK2V617F in MPN-blast phase samples (52%) compared to chronic phase (71%). Also, the percentage of patients with homozygous mutant JAK2 as a result of CNN-LOH was lower in the MPN-blast phase (43%) compared to the chronic phase (53%). Taken together, the data suggest that gain-of-function mutation of JAK2 is not a perquisite for leukemic transformation. Remarkably, CNN-LOH on either 7q or 9p was related to decreased survival after leukemic transformation (p=0.02 and p=0.012, respectively). Given the variety of allelic imbalances, our data suggest that MPN-blast phase appears to be a heterogeneous disease prone to have evolved multiple mechanisms to provide a proliferative advantage to the abnormal leukemic clone. Our analysis of MPN genomes in the chronic compared to the leukemic stage provided new prognostic insights, as well as novel causative genes which might be involved in the transformation to MPN-blast phase. Disclosures No relevant conflicts of interest to declare.
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome–negative myeloproliferative neoplasms
Thoennissen, Nils H., Krug, Utz , Lee, Dhong Hyun Tony, Kawamata, Norihiko , Iwanski, Gabriela B., Weiss, Tamara, Nowak, Daniel , Koren‐Michowitz, Maya , Kato, Motohiro , Sanada, Masashi , Nagler, Arnon , Raynaud, Sophie , Müller‐Tidow, Carsten , Haferlach, Torsten , Gilliland, D. Gary, Tefferi, Ayalew , Koeffler, H. Phillip , Lasho, Terra L. , Shih, Lee‐Yung , Mesa, Ruben A. , Ogawa, Seishi , Kato, Motohiro

Mayo Clinic

Blood | January 13, 2010 | Volume: 115 | Issue: 14 | Pages: 2882-2890

10.1182/blood-2009-07-235119 | PMID 20068225 Get It

Abstract Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and primary myelofibrosis show an inherent tendency for transformation into leukemia (MPN-blast phase), which is hypothesized to be accompanied by acquisition of additional genomic lesions. We, therefore, examined chromosomal abnormalities by high-resolution single nucleotide polymorphism (SNP) array in 88 MPN patients, as well as 71 cases with MPN-blast phase, and correlated these findings with their clinical parameters. Frequent genomic alterations were found in MPN after leukemic transformation with up to 3-fold more genomic changes per sample compared with samples in chronic phase (P < .001). We identified commonly altered regions involved in disease progression including not only established targets (ETV6, TP53, and RUNX1) but also new candidate genes on 7q, 16q, 19p, and 21q. Moreover, trisomy 8 or amplification of 8q24 (MYC) was almost exclusively detected in JAK2V617F− cases with MPN-blast phase. Remarkably, copy number–neutral loss of heterozygosity (CNN-LOH) on either 7q or 9p including homozygous JAK2V617F was related to decreased survival after leukemic transformation (P = .01 and P = .016, respectively). Our high-density SNP-array analysis of MPN genomes in the chronic compared with leukemic stage identified novel target genes and provided prognostic insights associated with the evolution to leukemia.